Abstract
While each route of therapeutic drug delivery has its own advantages and limitations, oral delivery is often favored because it offers convenient painless administration, sustained delivery, prolonged shelf life, and often lower manufacturing cost. Its limitations include mucus and epithelial cell barriers in the gastrointestinal (GI) tract that can block access of larger molecules including Therapeutic protein or peptide-based drugs (TPPs), resulting in reduced bioavailability. This review describes these barriers and discusses different strategies used to modify TPPs to enhance their oral bioavailability and/or to increase their absorption. Some seek to stabilize the TTPs to prevent their degradation by proteolytic enzymes in the GI tract by administering them together with protease inhibitors, while others modify TPPs with mucoadhesive polymers like polyethylene glycol (PEG) to allow them to interact with the mucus layer, thereby delaying their clearance. The further barrier provided by the epithelial cell membrane can be overcome by the addition of a cell-penetrating peptide (CPP) and the use of a carrier molecule such as a liposome, microsphere, or nanosphere to transport the TPP-CPP chimera. Enteric coatings have also been used to help TPPs reach the small intestine. Key efficacious TPP formulations that have been approved for clinical use will be discussed.
Subject
Pediatrics, Perinatology and Child Health
Reference195 articles.
1. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.
2. Peptide Synthesis Market by Product (Equipment and Reagents); by Technology (Hybrid & Recombinant Technology, Liquid-phase Peptide Synthesis and Solid-phase Peptide Synthesis); for Contract Development & Manufacturing Organizations, Academic & Research Institutes and Pharmaceutical & Biotechnological Companies: Global Industry Perspective, Comprehensive Analysis and Forecast, 2018–2025https://www.zionmarketresearch.com/report/peptide-synthesis-market
3. Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials;Aguirre;Adv. Drug Deliv. Rev.,2016
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献